

## **Product datasheet for TL318766**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **TNFRSF4 Human shRNA Plasmid Kit (Locus ID 7293)**

**Product data:** 

**Product Type:** shRNA Plasmids

Product Name: TNFRSF4 Human shRNA Plasmid Kit (Locus ID 7293)

**Locus ID:** 7293

Synonyms: ACT35; CD134; IMD16; OX40; TXGP1L

**Vector:** pGFP-C-shLenti (TR30023)

**E. coli Selection:** Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** TNFRSF4 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 7293).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 003327, NM 003327.1, NM 003327.2, NM 003327.3, BC105070, BC105070.1, BC040257,

BC105072, NM 003327.4

UniProt ID: P43489

**Summary:** The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor

has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of

apoptosis inhibitors BCL2 and BCL2IL1/BCL2-XL, and thus suppresses apoptosis. The

knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).